Arbutus Biopharma Corp reports results for the quarter ended June 30 - Earnings Summary

Arbutus Biopharma

06/08/2025 14:20

Arbutus Biopharma Corp ABUS.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -11 cents.  The mean expectation of five analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -7 cents to -2 cents per share.

Revenue rose 522.2% to $10.74 million from a year ago; analysts expected $1.59 million.

Arbutus Biopharma Corp's reported EPS for the quarter was 1 cent​.

The company reported quarterly net income of $2.52 million.

Arbutus Biopharma Corp shares had risen by 10.4% this quarter and gained 4.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 30.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00, about 31.8% above its last closing price of $3.41

This summary was machine generated from LSEG data August 6 at 01:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.05
0.01
Beat
Mar. 31 2025
-0.10
-0.13
Missed
Dec. 31 2024
-0.08
-0.07
Beat
Sep. 30 2024
-0.09
-0.09
Met